The study showed that differences exist among the tested active ingredients in their ability to moisturize the skin. These differences are dependent not only on the type and concentration of the active substance used but also on the type of vehicle in which they are applied. It was also found that the active substances influence the viscosity of the prepared formulations.

Summary Background Cosmetic products mean any substance or mixture intended to be placed in contact with the external parts of the human body (eg, epidermis, lips) and should not pass to the lower parts and penetrate to the skin. As a part of evaluation of cosmetic safety, the transdermal absorption of substances should be investigated. Materials and Methods In vitro absorption was investigated with Franz diffusion cells on untreated porcine skin and specimens of the same treated with 15%wt. SLS. The integrity of the skin was discerned by gauging transdermal electrical conductivity (TEC), the concentration of caffeine absorbed by the samples of skin membrane by liquid chromatography, which took place by applying an emulsion and/or a gel containing active hydration agents (urea, sodium hyaluronate, and sericin). Results The greatest extent of caffeine penetration was seen for pretreatment with just SLS; similar results were in skin treated with the base gel with 10%wt. urea. In the skin treated with the base emulsion only, the amount of caffeine absorbed was twofold less; this increased after adding the active hydration substances. The values measured for TEC corresponded with the amount of caffeine absorbed. Conclusion The gel proved to be the more potent vehicle for the active ingredient, as it demonstrated greater transdermal caffeine penetration than the emulsions, correlating with the degree of damage to the skin as detected by TEC.

The presence of panthenol in an o/w and w/o semisolid formulations significantly enhances skin barrier repair and hydration of the stratum corneum. Better vehicle for the active substance as regards hydration proved o/w formulations.

Background and Aims IL2-RA (Interleukin 2 receptor antagonist) are recommended for the induction immunosuppression of kidney transplant recipients in patients with low/standard immunological risk. Studies showing the effectiveness of these substances have often been performed in patients taking cyclosporine. We aimed to find out whether the same results would be obtained with the more effective tacrolimus in an immunosuppressive regimen. Method Induction immunosuppression using IL2-RA basiliximab in all patients undergoing kidney transplantation has been routinely used in our transplant center since April 1, 2018. We retrospectively compared outcomes of kidney transplantation of the last 40 patients before introduction of induction and the first 40 patients after the induction (monitored period of analysis is June 2017 to January 2019). All patients in each group received baseline immunosuppression of tacrolimus, corticosteroid and mycophenolate. We selected patients with low immunological risk (1st transplant, panel reactive antibodies up to 20%, without donor specific antibodies, donation after brain death) in both groups and evaluated their renal outcomes (serum creatinine and estimated glomerular filtration rate/eGFR) at 12 months after transplantation. Results Patients in the groups withnout and with basiliximab induction were of comparable age (51.9 years vs. 54.7) and with similar retransplantation rate (20%). The 1-year survival of patients and kidneys was the same (97.4% patient survival and 92.1% renal survival). Renal transplant function at 12 months was analyzed in 21 patients without and 19 patients with basiliximab induction with low baseline immunological risk. The patients who received basiliximab inductive immunosuppression had better graft function 12 months compared to patients without basiliximab administration: median serum creatinine level 112 µmol/L vs. 127 µmol/L (P=0.047) and eGFR 0.85 ml/s vs. 0.77 ml/s (P=0.347). Better renal function was also shown in the subgroup of patients older than 65 years. Conclusion At our transplant center, the introduction of basiliximab induction in patients at low immunological risk led to improved graft function in the short term despite the growing subpopulation of geriatric patients.